文献速递乳腺外科

实施BREASTChoice多层次乳房重建决策支持工具并个体化风险预测的随机对照试验

A Randomized Controlled Trial of the Implementation of BREASTChoice , a Multilevel Breast Reconstruction Decision Support Tool With Personalized Risk Prediction.
PubMed 文献 · Ann Surg · 2024-05-27

该多中心随机对照试验将BREASTChoice决策工具嵌入电子健康记录,纳入369例0-III期乳腺癌乳房切除患者,随机分为BREASTChoice组或对照网站组。BREASTChoice组知识得分在符合方案分析中高于对照组(均值71.4 vs 67.4,P=0.03),但在意向性治疗分析中差异未达统计学显著(均值70.6 vs 67.4,P=0.08)。工具未改善决策冲突、偏好与治疗匹配或共享决策,在高风险患者中符合方案分析显示使用BREASTChoice者选择重建的比例更少。

要点

  • BREASTChoice组知识得分在符合方案分析中高于对照组(均值71.4 vs 67.4,P=0.03)。
  • 意向性治疗分析中知识得分差异未达统计学显著(均值70.6 vs 67.4,P=0.08)。
  • 工具未改善决策冲突、偏好与治疗匹配或共享决策。

核心结论

  • BREASTChoice是一种整合风险预测、患者教育和临床医生参与的新型决策工具,使用该工具的患者知识水平更高,老年人和种族少数背景人群获益尤其明显,但对其他决策结局无影响。
  • 作者建议未来研究应克服实施障碍,并专门评估高风险患者的决策结局。

研究设计与样本

  • 多中心随机对照试验,纳入369例0-III期乳腺癌接受乳房切除术的成年女性,随机分为BREASTChoice组或对照网站组。
  • 25名符合条件临床医生中23名入组,761例 contacted 患者中369例(48%)入组并随机化,患者平均年龄51岁,15%年龄大于65岁。
  • 分析包括意向性治疗分析、符合方案分析(随机至BREASTChoice且访问工具者)和分层分析。

主要发现

  • BREASTChoice组知识得分在意向性治疗分析中均值70.6 vs 对照组67.4(P=0.08),在符合方案分析中均值71.4 vs 对照组67.4(P=0.03)。
  • 按中心分层时知识得分差异在意向性治疗分析中P=0.04、符合方案分析中P=0.01;按年龄分层时意向性治疗分析P=0.04、符合方案分析P=0.02;按种族分层时意向性治疗分析P=0.04、符合方案分析P=0.01。
  • BREASTChoice未改善决策冲突、偏好与治疗之间的匹配或共享决策。
  • 符合方案分析中,使用BREASTChoice的高风险患者选择重建的比例更少。
  • BREASTChoice可用性高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To implement the BREASTChoice decision tool into the electronic health record and evaluate its effectiveness. BACKGROUND: BREASTChoice , is a multilevel decision tool that: 1) educates patients about breast reconstruction; 2) estimates personalized risk of complications; 3) clarifies patient preferences; and 4) informs clinicians about patients' risk and preferences. METHODS: A multisite randomized controlled trial enrolled adult women with stage 0-III breast malignancy undergoing mastectomy. Participants were randomized to BREASTChoice or a control website. A survey assessed knowledge, preferences, decisional conflict, shared decision-making, preferred treatment, and usability. We conducted intent-to-treat (ITT), per-protocol (PP) analyses (those randomized to BREASTChoice who accessed the tool), and stratified analyses. RESULTS: 23/25 eligible clinicians enrolled. 369/761 (48%) contacted patients enrolled and were randomized. Patients' average age was 51 years; 15% were older than 65. BREASTChoice participants had higher knowledge than control participants (ITT: mean 70.6 vs. 67.4, P =0.08; PP: mean 71.4 vs. 67.4, P =0.03), especially when stratified by site (ITT: P =0.04, PP: P =0.01), age (ITT: P =0.04, PP: P =0.02), and race (ITT: P =0.04, PP: P =0.01). BREASTChoice did not improve decisional conflict, match between preferences and treatment, or shared decision-making. In PP analyses, fewer high-risk patients using BREASTChoice chose reconstruction. BREASTChoice had high usability. CONCLUSIONS: BREASTChoice is a novel decision tool incorporating risk prediction, patient education, and clinician engagement. Patients using BREASTChoice had higher knowledge; older adults and those from racially minoritized backgrounds especially benefitted. There was no impact on other decision outcomes. Future studies should overcome implementation barriers and specifically examine decision outcomes among high-risk patients.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Politi MC, Myckatyn TM, Cooksey K, et al. A Randomized Controlled Trial of the Implementation of BREASTChoice , a Multilevel Breast Reconstruction Decision Support Tool With Personalized Risk Prediction. Ann Surg. 2024. PMID: 38801247. doi:10.1097/SLA.0000000000006354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。